DRUG-DRUG INTERACTIONS IN PSYCHIATRIC PATIENTS: IDENTIFYING HIGH-RISK COMBINATIONS AND MITIGATION STRATEGIES

H SHAMSHAD; S SHAMSHAD

doi:10.54112/bcsrj.v2022i1.858

Authors

H SHAMSHAD Department of Computer Science, Sarhad University of Science & Information Technology, Peshawar 25000, Pakistan
S SHAMSHAD Department of Pharmacy, Lady Reading Hospital Peshawar 25000, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2022i1.858

Keywords:

Adverse Drug Event, Drug-Drug Interactions, Mental Health, Mitigation Strategies, Patient Safety, Psychiatric Patients, Psychotropic Drugs

Abstract

Psychiatric patients are at a high risk of severe adverse drug events (ADEs) due to potential drug-drug interactions (DDIs). These interactions can worsen existing health conditions and complicate treatment outcomes. Objective: This study aimed to identify and evaluate the drug-drug interactions (DDIs) of psychoactive drugs among mental health patients and propose effective prevention measures. A retrospective study was conducted at the Department of Pharmacy, Lady Reading Hospital, Peshawar, from January 1, 2021, to July 31, 2021. The study included all psychiatric patients treated during this period. Medication records were re-examined to identify drug-drug interactions (DDIs) using reliable drug interaction databases. Adverse effects resulting from these interactions were documented. Statistical analysis assessed the frequency and severity of the identified DDIs. Mitigation strategies were developed based on the probability and clinical relevance of the interactions. These strategies included drug adjustments, regular monitoring of patients, and patient education aimed at reducing the risk of adverse effects. The major DDIs frequently occur with commonly used psychiatric medications such as antipsychotics, antidepressants, and mood stabilisers. Common adverse effects included sedation, cardiovascular complications, and increased risk of serotonin syndrome. Mitigation measures, such as drug adjustment, regular monitoring, and patient education, were suggested to reduce the risk of adverse effects. Psychiatric patients are predisposed to severe ADEs due to DDIs, which are often difficult to predict. Mitigation measures such as appropriate drug adjustments and patient education are essential to enhance patient safety and treatment outcomes.

Downloads

Download data is not yet available.

References

Courlet, P., Livio, F., Alves Saldanha, S., Scherrer, A., Battegay, M., Cavassini, M., Stoeckle, M., Decosterd, L. A., and Marzolini, C. (2020). Real-life management of drug–drug interactions between antiretrovirals and statins. Journal of Antimicrobial Chemotherapy 75, 1972-1980.

Fasinu, P. S., Bouic, P. J., and Rosenkranz, B. (2012). An overview of the evidence and mechanisms of herb–drug interactions. Frontiers in pharmacology 3, 69.

Guo, J. J., Wu, J., Kelton, C. M., Jing, Y., Fan, H., Keck, P. E., and Patel, N. C. (2012). Exposure to potentially dangerous drug-drug interactions involving antipsychotics. Psychiatric Services 63, 1080-1088.

Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., and Gründer, G. (2011). AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 21, 195-235.

Jose de Leon, M., Sandson, N. B., and Cozza, K. L. Med-Psych Drug-Drug Interaction Update: A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics.

Khan, Q., Ismail, M., Haider, I., and Khan, F. (2017). Prevalence of QT interval prolonging drug–drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study. International journal of clinical pharmacy 39, 1256-1264.

Kooij, J., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balazs, J., Thome, J., Dom, G., Kasper, S., and Filipe, C. N. (2019). Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European psychiatry 56, 14-34.

Lee, H.-Y., Li, J.-H., Wu, L.-T., Wu, J.-S., Yen, C.-F., and Tang, H.-P. (2012). Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. Substance abuse treatment, prevention, and policy 7, 1-12.

Manolis, T. A., Manolis, A. A., and Manolis, A. S. (2019). Cardiovascular safety of psychiatric agents: a cautionary tale. Angiology 70, 103-129.

Protti, M., Mandrioli, R., Marasca, C., Cavalli, A., Serretti, A., and Mercolini, L. (2020). New‐generation, non‐SSRI antidepressants: Drug‐drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. Medicinal Research Reviews 40, 1794-1832.

Reeve, E., Moriarty, F., Nahas, R., Turner, J. P., Kouladjian O’Donnell, L., and Hilmer, S. N. (2018). A narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms. Expert opinion on drug safety 17, 39-49.

Sarkar, S. (2017). Psychiatric polypharmacy, etiology and potential consequences. Current Psychopharmacology 6, 12-26.

Singh, A. K. (2019). Alcohol interaction with cocaine, methamphetamine, opioids, nicotine, cannabis, and γ-hydroxybutyric acid. Biomedicines 7, 16.

van Tongeren, J., Harkes-Idzinga, S., van der Sijs, H., Atiqi, R., van den Bemt, B., Draijer, L., Hiel, D., Kerremans, A., Kremers, B., and de Leeuw, M. (2020). The development of practice recommendations for drug-disease interactions by literature review and expert opinion. Front. Pharmacol. 11, 707 (2020). POLICY AND PRACTICE REVIEWS published 15.

Wang, P. S., Bohn, R. L., Glynn, R. J., Mogun, H., and Avorn, J. (2001). Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. American Journal of Psychiatry 158, 892-898.

Zarkowski, P. A. (2020). Relative prevalence of 10 types of pharmacodynamic interactions in psychiatric treatment. The International Journal of Psychiatry in Medicine 55, 82-104.